Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial

@article{Franois2020NangibotideIP,
  title={Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial},
  author={Bruno François and Xavier Wittebole and Ricard Ferrer and Jean Paul Mira and Thierry Dugernier and Sébastien Gibot and Marc Derive and Aur{\'e}lie Olivier and Val{\'e}rie Cuvier and Stephan Witte and Peter Pickkers and François Vandenhende and Jean Jacques Garaud and Miguel S{\'a}nchez and Margarita Salcedo-Magguilli and Pierre-François Laterre},
  journal={Intensive Care Medicine},
  year={2020},
  volume={46},
  pages={1425-1437}
}
Purpose Nangibotide is a specific TREM-1 inhibitor that tempered deleterious host–pathogens interactions, restored vascular function, and improved survival, in animal septic shock models. This study evaluated the safety and pharmacokinetics of nangibotide and its effects on clinical and pharmacodynamic parameters in septic shock patients. Methods This was a multicenter randomized, double-blind, two-stage study. Patients received either continuous infusion of nangibotide (0.3, 1.0, or 3.0 mg/kg… Expand
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial
TLDR
Primary outcomes of the study will include efficacy of nangibotide in relation to sTREM-1 levels in terms of organ function, mortality and long-term morbidity, and the development of a novel platform for the measurement of sT REM-1 at the point of care. Expand
Increased sTREM-1 plasma concentrations are associated with poor clinical outcomes in patients with COVID-19
Abstract Patients with sepsis display increased concentrations of sTREM-1 (soluble Triggering Receptor Expressed on Myeloid cells 1), and a phase II clinical trial focusing on TREM-1 modulation isExpand
New Agents in Development for Sepsis: Any Reason for Hope?
TLDR
Within the entire sepsis drugs portfolio, those targeting the immune response are probably the most promising, and monoclonal antibodies targeting either cytokines or infectious agents are undoubtedly part of the potential successful therapeutic classes to come. Expand
Soluble triggering receptor expressed on myeloid cells-1 is a marker of organ injuries in cardiogenic shock: results from the CardShock Study
TLDR
High levels of circulating Triggering Receptor Expressed on Myeloid cells-1 (TREM-1), were associated with death in acute myocardial infarction confirming excessive inflammation as determinant of bad outcome. Expand
sTREM-1 is a specific biomarker of TREM-1 pathway activation
TLDR
The results suggest that sTREM-1 release depends on the activation and dimerization of the receptor and is a marker of TREM- 1 receptor activation, which is a key step in allowing its activation and the transduction of intracellular signals. Expand
TREM-1 isoforms in bacterial infections: to immune modulation and beyond
TLDR
An updated insight is provided into how the receptor influences and is influenced by bacterial infections, highlighting the advances regarding the use/manipulation of TREM-1 isoforms in biomedical research and clinical practice. Expand
Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives
TLDR
This review wants to report the update on these novel APIs, focusing on the molecules in clinical development, representing the direct consequence of the drug discovery process of the last 10 years. Expand
Potentiation of NETs release is novel characteristic of TREM-1 activation and the pharmacological inhibition of TREM-1 could prevent from the deleterious consequences of NETs release in sepsis
TLDR
It is reported that TREM-1 potentiates NET release by human and murine neutrophils and is a component of the NET structure, and may constitute a new therapeutic target to prevent NETosis and associated endothelial dysfunction. Expand
Novel Diagnostics and Therapeutics in Sepsis
TLDR
Cutting edge diagnostics and therapeutics in development may improve time to diagnosis and address two broad management principles: source control by removing the molecular infectious stimulus of sepsis, and attenuation of the pathological immune response allowing the body to heal. Expand
TREM-1 orchestrates Angiotensin II-induced monocyte trafficking and promotes experimental abdominal aortic aneurysm.
TLDR
TREM-1 is involved in AAA pathophysiology and may represent a promising therapeutic target in human, as detected in mouse aortic aneurysm and colocalizes with macrophages. Expand
...
1
2
...

References

SHOWING 1-10 OF 52 REFERENCES
Drotrecogin alfa (activated) in adults with septic shock.
TLDR
DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock, and rates of death at 28 and 90 days were not significantly different in other predefined subgroups, including patients at increased risk for death. Expand
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
TLDR
Among patients with severe sepsis, the use of eritoran, compared with placebo, did not result in reduced 28-day mortality, and no significant differences were observed in any of the prespecified subgroups. Expand
Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.
TLDR
This is the first trial of an immunoadjuvant therapy targeting defects in adaptive immunity in patients with sepsis and CYT107 reversed the marked loss of CD4+ and CD8+ immune effector cells, a hallmark of septic shock and a likely key mechanism in its morbidity and mortality. Expand
Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial
Rationale: There remains uncertainty about the role of corticosteroids in sepsis with clear beneficial effects on shock duration, but conflicting survival effects. Two transcriptomic sepsis responseExpand
Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial.
TLDR
Among patients with sepsis-associated coagulopathy, administration of a human recombinant thrombomodulin, compared with placebo, did not significantly reduce 28-day all-cause mortality. Expand
Effects of a TREM-Like Transcript 1–Derived Peptide During Hypodynamic Septic Shock in Pigs
TLDR
Cardiovascular failure was dampened as attested by a better mean arterial pressure, cardiac index, cardiac power index, and SvO2, despite lower norepinephrine requirements. Expand
Immunotherapy: A promising approach to reverse sepsis-induced immunosuppression.
TLDR
targeting immunosuppression provides a logical approach to treat protracted sepsis and discusses the potential immunotherapeutic agents to boost T cell function during sepsi and improve host resistance to infection. Expand
Time course of immature platelet count and its relation to thrombocytopenia and mortality in patients with sepsis
TLDR
Thrombopoietic activity was generally maintained in the acute phase of sepsis, and a decrease in AIPC after admission was independently associated with the development of severe thrombocytopenia and mortality, suggesting the importance of suppressed throm bopoiesis in the pathophysiology of septicaemia. Expand
Soluble TREM-1 Serum Level can Early Predict Mortality of Patients with Sepsis, Severe Sepsis and Septic Shock
Early prognostic prediction of sepsis is essential in adjusting therapeutic protocols to prevent deterioration and reduce mortality. We compared the predictive value of the serum concentration of theExpand
Attenuation of Responses to Endotoxin by the Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor LR12 in Nonhuman Primate
TLDR
The triggering receptor expressed on myeloid cells-1 inhibitor LR12 is able to mitigate endotoxin-associated clinical and biological alterations, with no obvious side effects, which paves the way for future phases Ia and Ib trials in humans. Expand
...
1
2
3
4
5
...